Israel-based RedHill Biopharma Ltd. (Nasdaq: RDHL) announced a private placement of ADSs and accompanying warrants with potential gross proceeds of up to USD 19.4 million, structured to support a possible strategic product acquisition and sustain pipeline and commercial operations. The transaction follows a period of sustained cash pressure — RedHill reported a cash balance of USD 4.1 million at year-end 2025 — and reflects continued reliance on equity capital markets since the 2023 divestiture of Movantik.
The offering comprises 8,571,429 ADSs at USD 0.70 per ADS, generating USD 6 million in upfront gross proceeds before placement agent fees, and two warrant tranches that if fully exercised would yield up to approximately USD 13.4 million in additional proceeds.
Company overview and pipeline
RedHill is a specialty biopharmaceutical company with dual headquarters in Tel Aviv, Israel and Raleigh, North Carolina, focused on gastrointestinal diseases, infectious diseases, and oncology. Its commercial asset, Talicia (omeprazole magnesium, amoxicillin and rifabutin), is the FDA-approved leading branded H. pylori therapy prescribed by US gastroenterologists, now co-commercialized through Talicia Holdings Inc., a joint venture with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill retains a 70% interest in the venture.